Epizyme, Inc. (the “ Company”), entered into an Agreement and Plan of Merger (Merger Agreement), by and among the Company, Ipsen Pharma SAS (the Parent) and wholly owned subsidiary of Ipsen S.A. (Ipsen S.A), and Hibernia Merger Sub, Inc., a Delaware corporation (Purchaser) and wholly owned subsidiary of Ipsen Biopharmaceuticals, Inc. In accordance with the terms of the Merger Agreement, (i) each of Ken Bate, Roy Beveridge, Grant Bogle, Kevin Conroy, Michael Giordano, Carl Goldfischer, Pablo Legorreta, David Mott, Victoria Richon and Carol Stuckley ceased to serve in his or her respective position as a member of the Company's Board of Directors, and any committee thereof effective as of the Effective Time, and (ii) Francois Garnier and Aymeric Le Chatelier, each a director of the Purchaser immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time. In accordance with the terms of the Merger Agreement, Christelle Huguet and Jennifer Benenson, each an officer of the Purchaser immediately prior to the Effective Time, became officers of the Company, in each case, effective as of the Effective Time. Further, pursuant to a unanimous written consent of the Company's Board of Directors, dated as of August 12, 2022, Christelle Huguet and Jennifer Benenson were appointed as President and Secretary and Treasurer, respectively, of the Company, effective as of immediately following the consummation of the Merger.